ArriVent Q3 net loss widens to $40.3 million as Phase 3 FURVENT trial misses goal
ArriVent reported third-quarter 2026 results with a net loss of $40.3 million, up from $35.0 million a year earlier, as research and development and general and administrative expenses rose. The company also said its Phase 3 FURVENT trial of firmonertinib did not meet its primary endpoint of progression-free survival, and that Stuart Lutzker, its President of Research and Development and a director, will retire effective December 1, 2026. For shareholders, the trial miss is the central development, with the wider loss and leadership change adding to the negative picture.
Key points
- FURVENT missed its primary endpoint of progression-free survival by blinded independent central review; median PFS was 11.0 months at 240 mg versus 9.5 months with chemotherapy (HR 0.75; p=0.0654).
- Q3 2026 net loss was $40.3 million versus $35.0 million in Q3 2025; collaboration revenue was $5.0 million versus none a year earlier.
- Net loss per share was $0.81 versus $0.83 a year earlier; cash and investments were $393.2 million at September 30, 2026, expected to fund operations to mid-2028.
- Dr. Stuart Lutzker retires effective December 1, 2026, with a one-time payment of $428,438.21 under a planned retirement agreement; Chief Medical Officer Priti Patel, M.D., will lead R&D from that date.
The filing
Written by AI on Nov 9, 2026, 6:16 PM ET, from this filing only.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.